Cystografin

Cystografin

Cystografin Recall

Get an alert when a recall is issued.

Questions & Answers

Side Effects & Adverse Reactions

Severe sensitivity reactions are more likely to occur in patients with a personal or family history of bronchial asthma, significant allergies, or previous reactions to contrast agents.

A history of sensitivity to iodine per se or to other contrast agents is not an absolute contraindication to the use of diatrizoate meglumine, but calls for extreme caution in administration.

Legal Issues

There is currently no legal information available for this drug.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

Cystografin is indicated for retrograde cystourethrography.

History

There is currently no drug history available for this drug.

Other Information

Cystografin is a radiopaque contrast agent supplied as a sterile, clear, colorless to pale yellow, mobile or slightly viscous solution. Each mL provides 300 mg diatrizoate meglumine with 0.4 mg edetate disodium as a sequestering agent. Each mL of solution also contains approximately 141 mg organically bound iodine. At the time of manufacture, the air in the container is replaced by nitrogen. The preparation should be protected from strong light.

Cystografin Manufacturers


  • Bracco Diagnostics Inc
    Cystografin (Diatrizoate Meglumine) Injection, Solution [Bracco Diagnostics Inc]

Login To Your Free Account